» Articles » PMID: 28120185

Drug Therapy for Stable Angina Pectoris

Overview
Journal Drugs
Specialty Pharmacology
Date 2017 Jan 26
PMID 28120185
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic stable angina pectoris refers to the predictable, reproducible occurrence of pressure or a choking sensation in the chest or adjacent areas caused by myocardial ischemia in association with physical or emotional stress, and cessation of exertion and or sublingual nitroglycerin invariably relieves the discomfort. It is a common presenting symptom of severe narrowing of one or more coronary arteries, non-obstructive coronary arteries, or even when the coronary arteries are angiographically normal. Patients often avoid activities which precipitate symptoms and have impaired quality of life. Most patients with angina pectoris can be managed with lifestyle changes, especially abstinence from smoking and regular exercise, and anti-anginal drugs. However, the choice of initial or combination antianginals as recommended in the guidelines is not evidence based. In addition, patients with stable angina due to coronary artery disease should also receive aspirin and a statin. Treatment of patients with angina and normal coronary arteries remains to be established. The aim of this article is to provide the readers not only with a guideline-based approach, which varies from one country to another, but also an individual-based approach, which takes into consideration circulatory status and the presence or absence of comorbidities in the treatment decision-making process. This manuscript primarily deals with drug therapy of stable angina pectoris and not coronary artery revascularization, which also provides angina relief but is usually reserved for patients who fail to respond to adequate drug therapy.

Citing Articles

Clinical Outcomes of Calcium-Channel Blocker vs Beta-Blocker: From the Korean Acute Myocardial Infarction Registry.

Kim M, Yuan S, Lee K, Jin X, Song Z, Cho Y JACC Asia. 2023; 3(3):446-454.

PMID: 37396422 PMC: 10308128. DOI: 10.1016/j.jacasi.2023.02.006.


Analysis of acupoint selection and prescription rules of acupuncture for treatment of stable angina pectoris based on a Traditional Chinese Medicine inheritance calculation platform: A systematic review.

Yang K, Zhang L, Li B, Liu T, Chao Y, Li W Medicine (Baltimore). 2023; 101(49):e31466.

PMID: 36626434 PMC: 9750679. DOI: 10.1097/MD.0000000000031466.


Saudi Heart Association Guidelines on Best Practices in the Management of Chronic Coronary Syndromes.

AlShammeri O, Al Saif S, Al Shehri H, Alasng M, Qaddoura F, Al Shehri M J Saudi Heart Assoc. 2022; 34(3):182-211.

PMID: 36578770 PMC: 9762239. DOI: 10.37616/2212-5043.1320.


Exploring the "gene-protein-metabolite" network of coronary heart disease with phlegm and blood stasis syndrome by integrated multi-omics strategy.

Yang G, Zhou S, He H, Shen Z, Liu Y, Hu J Front Pharmacol. 2022; 13:1022627.

PMID: 36523490 PMC: 9744761. DOI: 10.3389/fphar.2022.1022627.


Effects of Shexiang Baoxin Pill for Coronary Microvascular Function: A Systematic Review and Meta-Analysis.

Wang M, Shan Y, Sun W, Han J, Tong H, Fan M Front Pharmacol. 2021; 12:751050.

PMID: 34795585 PMC: 8592925. DOI: 10.3389/fphar.2021.751050.


References
1.
Weisz G, Farzaneh-Far R, Ben-Yehuda O, deBruyne B, Montalescot G, Lerman A . Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. Am Heart J. 2013; 166(6):953-959.e3. DOI: 10.1016/j.ahj.2013.08.004. View

2.
. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002; 359(9314):1269-75. DOI: 10.1016/S0140-6736(02)08265-X. View

3.
. The beta-blocker heart attack trial. beta-Blocker Heart Attack Study Group. JAMA. 1981; 246(18):2073-4. View

4.
Stone P, Gratsiansky N, Blokhin A, Huang I, Meng L . Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006; 48(3):566-75. DOI: 10.1016/j.jacc.2006.05.044. View

5.
Kloner R . Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004; 110(19):3149-55. DOI: 10.1161/01.CIR.0000146906.42375.D3. View